The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
An updated catalog of prostate cancer predictive tools
Abstract
Accurate estimates of risk are essential for physicians if they are to recommend a specific management to patients with prostate cancer. Accurate risk estimates also are required for clinical trial design to ensure that homogeneous, high‐risk patient groups are used to investigate new cancer therapeutics. Using the MEDLINE database, a literature search was performed on prostate cancer predictive tools from January 1966 to July 2007. The authors recorded input variables, the prediction form, the number of patients used to develop prediction tools, the outcome being predicted, prediction tool‐specific features, predictive accuracy, and whether validation was performed. Each prediction tool was classified into patient clinical disease state and the outcome being predicted. First, the authors described the criteria for evaluation (predictive accuracy, calibration, generalizability, head‐to‐head comparison, and level of complexity) and the limitations of current predictive tools. The literature search generated 109 published prediction tools, including only 68 that had undergone validation. An increasing number of predictive tools addressed important endpoints, such as disease recurrence, metastasis, and survival. Despite their limitations and the limitations of data, predictive tools are essential for individualized, evidence‐based medical decision making. Moreover, the authors recommend wider adoption of risk‐prediction models in the design and implementation of clinical trials. Among prediction tools, nomograms provide superior, individualized, disease‐related risk estimations that facilitate management‐related decisions. Nevertheless, many more predictive tools, comparisons between them, and improvements to existing tools are needed. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Internal validation of predictive models
Steyerberg, E. W., Harrell, F. E., Borsboom, G. J. J. M., Eijkemans, M. J. C., Vergouwe, Y., & Habbema, J. D. F. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00341-9 · Cited by 2,746
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Self-citationConsensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
Partin, A. W., Mangold, L. A., Lamm, D. M., Walsh, P. C., Epstein, J. I., & Pearson, J. D. (2001) · Urology · doi:10.1016/s0090-4295(01)01441-8 · Cited by 1,038
Cited by
Uno, H., Cai, T., Pencina, M. J., D'Agostino, R. B., & Wei, L. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4154 · Cited by 1,535
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Collins, G. S., de Groot, J. A., Dutton, S., Omar, O., Shanyinde, M., Tajar, A., Voysey, M., Wharton, R., Yu, L.-M., Moons, K. G., et al. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-40 · Cited by 729
Collins, G. S., Ogundimu, E. O., & Altman, D. G. (2016) · Statistics in Medicine · doi:10.1002/sim.6787 · Cited by 665
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C., Bangma, C., & Kataja, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 600
Cooperberg, M. R., Hilton, J. F., & Carroll, P. R. (2011) · Cancer · doi:10.1002/cncr.26169 · Cited by 457
Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA
Tomlins, S. A., Aubin, S. M. J., Siddiqui, J., Lonigro, R. J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001970 · Cited by 350
Knezevic, D., Goddard, A. D., Natraj, N., Cherbavaz, D. B., Clark-Langone, K. M., Snable, J., Watson, D., Falzarano, S. M., Magi-Galluzzi, C., Klein, E. A., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-690 · Cited by 339
Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4252 · Cited by 283
Lynam, A. L., Dennis, J. M., Owen, K. R., Oram, R. A., Jones, A. G., Shields, B. M., & Ferrat, L. A. (2020) · Diagnostic and Prognostic Research · doi:10.1186/s41512-020-00075-2 · Cited by 142
Machine learning in prostate MRI for prostate cancer: current status and future opportunities
Li, H., Lee, C. H., Chia, D., Lin, Z., Huang, W., & Tan, C. H. (2022) · Diagnostics · doi:10.3390/diagnostics12020289 · Cited by 74
Metadata
- Authors
- Shariat, S. F., Karakiewicz, P. I., Roehrborn, C. G., & Kattan, M. W.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-09-29
- Volume
- 113
- Issue
- 11
- Pages
- 3075-3099
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2057672608
- Cited by
- 264
- References
- 97
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.